This third issue of our monthly Life Science Patent Highlights. As always, the most recent documents might become available at the European Patent Office only a few days after this analysis goes online. PLEASE CITE AS: Mucke HAM. Patent Highlights for January. Published online in the H.M. Pharma Consultancy Blog (http://hmpharmacon.blogspot.com) on February 26, 2011. Contact us at office@hmpharm...

Insight Pharma Reports has published the latest of our technology and market assessment reports: Advanced Drug Delivery Technologies: Enabling Drug Reformulations and Administration Routes. A detailed description of its contents can be found here.As I have stated several times on this blog (last time, here), the classical concept of pharmaceutical innovation - as measured by drug approvals base...

Pfizer's announcement of its plans to shut down its Sandwich (Kent, UK) facility - which since its establishment in 1954 had developed into a hub of corporate life science R&D in Europe - continues to provoke outcries of all sorts.What seems to get lost in the hue and cry about 2,400 researchers and their supporting staff facing layoff (or, in a few selected cases, offers for relocation to th...

This is the second issue of our monthly Life Science Patent Highlights. Whenever possible we are now linking to ChemSpider for chemical structures and key data of investigational compounds. You can perform a lot of deeper chemistry-based searches on this free platform.PLEASE CITE AS: Mucke, HAM. Patent Highlights for January 2011. H.M. Pharma Consultancy. URL:http://hmpharmacon.blogspot.com/2011...

As some of those who are on LinkedIn, and specifically the members of the discussion group " Drug repurposing - reprofiling - repositioning," are already aware we are currently debating how a database on drug repurposing candidates could best be established. To be exact, this database would compile data on active ingredients of discontinued drugs or drug candidates. This is only a subset of all po...

While browsing the pharmaceutical news from the very first days of this new year, I had a "mosaic experience." This is my name for the mental self-assembly process that connects seemingly disparate pieces of information to form a general impression. Here are four pieces, all from the first week of 2011:The United States FDA approved fewer new chemical entities and biologics in 2010 than in the tw...

We've had some very encouraging feedback on our first batch of life science & technology patent highlights, published on January 3rd. Thank you! Please link to our blog and recommend it. The next issue, covering international patent applications published in January, will go online on February 1. We have been asked - indirectly at least - what interest H.M. Pharma Consultancy, a for-profit org...

This is the first monthly posting in what we intend to become a regular series of patent highlights, a showcase of the intellectual property we have been reviewing during the past month. We hope that it will be useful to the public. PLEASE CITE AS: Mucke HAM. Patent Highlights for December 2010. Published online in the H.M. Pharma Consultancy Blog (http://hmpharmacon.blogspot.com) on January 3, 2...

In this post six weeks ago, we had announced that H.M. Pharma Consultancy is considering a free "patent highlight" service, consisting of pointers to (and brief discussions of) very recently published medical, pharmaceutical and life science patent documents which we believe stand out from the huge amount of intellectual property documents that is pushed out by the patent offices. Well, our consi...

Exactly one week ago we founded the professional networking group "Drug Repurposing - Reprofiling - Repositioning" on LinkedIn, and I am happy to tell you that it was an immediate success. No less than 17 people joined during the first three days of the group`s existence -- and that was over a weekend! Today we stand at 41 members, and whats even more important, every single one of those is a per...